Clinical trials: Anti-Retroviral Agents
HIV-Associated Lipodystrophy Syndrome, HIV Infections
Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
The aim of this randomized study is to compare the effect of pioglitazone versus placebo on change in limb fat in HIV 1-infected patients treated with antiretroviral therapy for at least 6 months and with clinical lipoatrophy.
- Trial name
- NCT00148850
- Testing
- Pioglitazone
- Where
- France
- Volunteers
- 130 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Development of Resistance Mutations in Pregnant HIV-positive (+) Women Following Perinatal Antiretroviral Therapy in Israel
It has been shown that treatment of HIV-positive women with antiretroviral medication during pregnancy reduces the risk of HIV transmission to the child.
- Trial name
- NCT00197366
- Where
- 5 sites in Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
HIV-1-infection
Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
For people living with HIV, antiretroviral therapy (ART) helps to stop the virus from multiplying. The goal of current HIV treatment is to have such a small amount of the virus in the blood that it does not show up on regular…
- Trial name
- ACACIA (NCT06205602)
- Testing
- 3BNC117-LS, 10-1074-LS
- Where
- 4 sites in Botswana, South Africa
- Volunteers
- 135 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)
PRIMARY: To study the safety and tolerance of delavirdine mesylate ( U-90152 ) monotherapy. To compare the anti-HIV activity of three blood concentration levels of this agent with nucleoside analog monotherapy, either zidovudine…
- Trial name
- NCT00000810
- Testing
- Delavirdine mesylate, Zidovudine, Didanosine
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give calanolide A to HIV-infected adults who have not used anti-HIV drugs in the past.
- Trial name
- NCT00005120
- Testing
- Calanolide A
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Sarawak MediChem Pharmaceuticals
HIV-1 Infection
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
The purpose of this study is to determine whether a two-week course of disulfiram will reduce the HIV-1 latent reservoir in patients on highly active antiretroviral therapy (HAART).
- Trial name
- NCT01286259
- Testing
- Disulfiram
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
HIV-1-infection
Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).
Multicenter, parallel group, randomised, open label, study. Twenty-five clinical centers constituting the InAction network will participate the study.
- Trial name
- P25-INACTION (NCT04225325)
- Testing
- SYMTUZA, DESCOVY+DOLUTEGRAVIR, SYMTUZA+DOLUTEGRAVIR
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- ADRIANO LAZZARIN, MD
HIV, HIV-1
Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.
The purpose of this study is to evaluate the non-inferiority of ritonavir-boosted GS-9137 relative to a ritonavir-boosted Comparator Protease Inhibitor when used as part of combination antiretroviral regimens in subjects who have…
- Conditions
- HIV, HIV-1, Human Immunodeficiency Virus
- Trial name
- NCT00298350
- Testing
- GS-9137 - A Novel HIV-1 Integrase Inhibitor
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 278 people
- Sponsor
- Gilead Sciences
Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus
Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
Background: The human immunodeficiency virus (HIV) causes acquired immune deficiency syndrome (AIDS). Combination antiretroviral therapy (ART) drugs treat HIV infection.
- Conditions
- Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, AIDS Virus, Human Immunodeficiency Virus
- Trial name
- NCT01976715
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Seropositivity
Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV
The goal of this phase II, open-label, randomized, controlled clinical trial is to evaluate the impact of Gammora®, a 16-mer HIV integrase-derived peptide associated with a boosted darunavir antiretroviral regimen compared…
- Trial name
- NCT06799650
- Testing
- Gammora®
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Federal University of São Paulo
HIV Infection
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)
The purpose of this study is to investigate the efficacy, safety, and tolerability of an investigational treatment for patients with HIV.
- Trial name
- NCT00443703
- Testing
- MK0518 (raltegravir), Comparator: KALETRA™ (lopinavir (+) ritonavir )
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine
This study will see how safe and effective against HIV the drugs L-756423 plus indinavir (IDV) are compared to just IDV when taken with stavudine (d4T) and lamivudine (3TC).
- Trial name
- NCT00002424
- Testing
- L-756423, Indinavir sulfate, Lamivudine
- Where
- 16 sites in United States
- Volunteers
- 186 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Use of Incentives to Retain Drug Users in HIV Therapy
In many urban centres including Vancouver's Downtown Eastside, there is a high rate of HIV infection among users of illicit drugs.
- Trial name
- Incentives-2 (NCT01488942)
- Testing
- monetary reinforcer
- Where
- Canada
- Volunteers
- 139 people
- Sponsor
- University of British Columbia
Hepatitis C, HIV
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
This study aims to provide the evidence that 150mg of cobicistat will have the same effect on the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with atazanavir 300mg.
- Trial name
- DATE-4 (NCT02565888)
- Testing
- Daclatasvir, Atazanavir, Ritonavir
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
HIV, Zidovudine Adverse Reaction
Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients
The primary objective of the study is to compare the tolerance and safety between a low-dose Zidovudine (AZT) containing regimen (200 mg BID) and a standard dosage (300 mg BID) in HIV patients initiating a first line…
- Trial name
- AZTlowdose (NCT01540240)
- Testing
- Zidovudine
- Where
- Cameroon
- Volunteers
- 136 people
- Sponsor
- University Hospital, Geneva
HIV Infection, Acquired Immunodeficiency Syndrome
Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)
The PIVOT trial aims to determine whether a strategy of switching to PI monotherapy is non-inferior to continuing triple-therapy, in terms of the proportion of patients who maintain all the drug treatment options that were…
- Trial name
- PIVOT (NCT01230580)
- Testing
- Protease Inhibitor, Standard-of-care Antiretroviral therapy
- Volunteers
- 587 people
- Sponsor
- Medical Research Council
HIV Infections
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
- Trial name
- NCT00059462
- Testing
- Interleukin-2 SA, HAART
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 56 people
- Sponsor
- Bayer
HIV Infections
Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities
The purpose of this study is to determine the effectiveness of several anti-HIV treatment strategies in resource-poor South African communities.
- Trial name
- NCT00255840
- Testing
- Monitoring by an HIV-trained medical doctor, Monitoring by an HIV-trained primary care nurse, Efavirenz
- Volunteers
- 812 people
- Sponsor
- CIPRA SA
HIV Infections
Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection
Pilot study to evaluate the impact of extremely early ART in the dynamics of viral reservoir, immune activation and inflammation in patients with HIV-1 infection of less than 20 days (Fiebig stages I-II) compared to patients with…
- Trial name
- VIRECURE (NCT02588820)
- Testing
- Antiretroviral Therapy (Experimental)
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- David Garcia Cinca
HIV/AIDS, Antiretroviral Therapy
Revised Simplified Algorithm for Treatment Eligibility for HIV (SLATEII)
In its 2017 revision of the global guidelines for HIV care and treatment, the World Health Organization called for rapid or same-day initiation of antiretroviral treatment (ART) for eligible patients testing positive for HIV.
- Trial name
- SLATEII (NCT03315013)
- Testing
- SLATE II
- Where
- South Africa
- Volunteers
- 600 people
- Sponsor
- Boston University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.